NIH Policies and Regulatory Pathways for the Advancement of Radiation Medical Countermeasures and Biodosimetry Tools to U.S. FDA Licensure
- PMID: 34919721
- PMCID: PMC9762489
- DOI: 10.1667/RADE-21-00206.1
NIH Policies and Regulatory Pathways for the Advancement of Radiation Medical Countermeasures and Biodosimetry Tools to U.S. FDA Licensure
References
-
- Radiation biodosimetry medical countermeasure devices - Guidance for industry and Food and Drug Administration staff. Report No.: US Food and Drug Administration, Health and Human Services; 2016.
-
- Hrdina CM, Coleman CN, Bogucki S, Bader JL, Hayhurst RE, Forsha JD, et al. The “RTR” medical response system for nuclear and radiological mass-casualty incidents: a functional TRiage-TReatment-TRansport medical response model. Prehosp Disaster Med 2009; 24, 167–78. - PubMed
-
- Case C Jr., Radiation Injury Treatment Network(R): Preparedness through a coalition of cancer centers. Health Phys 2016; 111, 145–8. - PubMed
-
- Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER) Product development under the animal rule - Guidance for industry. Silver Spring, MD:2015.
-
- Plett PA, Chua HL, Sampson CH, Katz BP, Fam CM, Anderson LJ, et al. PEGylated G-CSF (BBT-015), GM-CSF (BBT-007), and IL-11 (BBT-059) analogs enhance survival and hematopoietic cell recovery in a mouse model of the hematopoietic syndrome of the acute radiation syndrome. Health Phys 2014; 106, 7–20. - PMC - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources